Clinical-stage neuroscience company developing small-molecule therapies for autism spectrum disorder, schizophrenia, and other CNS conditions.
Company Info
Upcoming Milestones & Key Dates
FDA meeting on ML-004 in autism
Phase 2 data readout for ML-004
Clinical Development Pipeline
Recent News
MapLight Therapeutics will meet with the FDA to chart a path forward for its autism drug after a disappointing Phase 2 readout, weighing trial-design changes and next-step options.
MapLight Therapeutics will meet with the FDA to discuss next steps for its autism drug despite a Phase 2 disappointment.
Leadership Team
Chief Executive Officer
Careers & Job Openings